pI: 9.0743 |
Length (AA): 252 |
MW (Da): 28981 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 7
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_126732)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G06460 | membrane-associated elongase-like protein |
Arabidopsis thaliana | AT3G06470 | GNS1/SUR4 membrane protein family |
Candida albicans | CaO19.6343 | one of three potential fatty acid elongase genes |
Candida albicans | CaO19.13699 | one of three potential fatty acid elongase genes |
Caenorhabditis elegans | CELE_F56H11.3 | Protein ELO-7, isoform B |
Dictyostelium discoideum | DDB_G0271066 | hypothetical protein |
Dictyostelium discoideum | DDB_G0270312 | GNS1/SUR4 family protein |
Drosophila melanogaster | Dmel_CG31522 | CG31522 gene product from transcript CG31522-RF |
Drosophila melanogaster | Dmel_CG2781 | CG2781 gene product from transcript CG2781-RA |
Drosophila melanogaster | Dmel_CG32072 | Elongase 68alpha |
Drosophila melanogaster | Dmel_CG11801 | Elongase 68beta |
Echinococcus granulosus | EgrG_000347100 | elongation of very long chain fatty acids |
Echinococcus multilocularis | EmuJ_000347100 | elongation of very long chain fatty acids |
Homo sapiens | ENSG00000118402 | ELOVL fatty acid elongase 4 |
Homo sapiens | ENSG00000197977 | ELOVL fatty acid elongase 2 |
Homo sapiens | ENSG00000164181 | ELOVL fatty acid elongase 7 |
Leishmania braziliensis | LbrM.05.1160 | fatty acid elongase, putative |
Leishmania braziliensis | LbrM.32.1310 | long chain polyunsaturated fatty acid elongation enzyme-like protein |
Leishmania donovani | LdBPK_051160.1 | elongation of very long chain fatty acids protein, putative |
Leishmania donovani | LdBPK_321220.1 | long chain polyunsaturated fatty acid elongation enzyme-like protein |
Leishmania infantum | LinJ.05.1160 | fatty acid elongase, putative |
Leishmania infantum | LinJ.32.1220 | long chain polyunsaturated fatty acid elongation enzyme-like protein |
Leishmania major | LmjF.32.1160 | long chain polyunsaturated fatty acid elongation enzyme-like protein |
Leishmania major | LmjF.05.1170 | fatty acid elongase, putative |
Leishmania mexicana | LmxM.05.1170 | elongation of very long chain fatty acids protein, putative |
Leishmania mexicana | LmxM.31.1160 | long chain polyunsaturated fatty acid elongation enzyme-like protein |
Mus musculus | ENSMUSG00000021696 | ELOVL family member 7, elongation of long chain fatty acids (yeast) |
Mus musculus | ENSMUSG00000021364 | elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 |
Mus musculus | ENSMUSG00000032262 | elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 4 |
Neospora caninum | NCLIV_017540 | elongation of very long chain fatty acids 4 protein, putative |
Plasmodium berghei | PBANKA_0104700 | long chain polyunsaturated fatty acid elongation enzyme, putative |
Plasmodium falciparum | PF3D7_0605900 | long chain polyunsaturated fatty acid elongation enzyme, putative |
Plasmodium knowlesi | PKNH_1144300 | long chain polyunsaturated fatty acid elongation enzyme, putative |
Plasmodium vivax | PVX_113465 | long chain polyunsaturated fatty acid elongation enzyme, putative |
Plasmodium yoelii | PY00625 | hypothetical protein |
Saccharomyces cerevisiae | YCR034W | fatty acid elongase ELO2 |
Schistosoma japonicum | Sjp_0095000 | Elongation of very long chain fatty acids protein AAEL008004, putative |
Schistosoma japonicum | Sjp_0062200 | ko:K10249 elongation of very long chain fatty acids protein 4, putative |
Schistosoma japonicum | Sjp_0314970 | Elongation of very long chain fatty acids protein 7, putative |
Schistosoma japonicum | Sjp_0044090 | ko:K10250 elongation of very long chain fatty acids protein 7, putative |
Schistosoma mansoni | Smp_010770.2 | elongation of fatty acids protein 1 |
Schistosoma mansoni | Smp_051810 | elongation of fatty acids protein 1 |
Schistosoma mansoni | Smp_010770.1 | fatty acid acyl transferase-related |
Schmidtea mediterranea | mk4.004143.00 | |
Schmidtea mediterranea | mk4.005022.00 | |
Schmidtea mediterranea | mk4.009946.01 | Elongation of very long chain fatty acids protein 4 |
Schmidtea mediterranea | mk4.054857.00 | Elongation of fatty acids protein 1 |
Schmidtea mediterranea | mk4.016012.00 | |
Schmidtea mediterranea | mk4.006666.02 | Elongation of fatty acids protein 1 |
Schmidtea mediterranea | mk4.005022.01 | |
Schmidtea mediterranea | mk4.004734.03 | |
Schmidtea mediterranea | mk4.009918.00 | Elongation of very long chain fatty acids protein 4 |
Schmidtea mediterranea | mk4.006478.00 | |
Trypanosoma brucei gambiense | Tbg972.5.6070 | elongation of very long chain fatty acids protein, putative |
Trypanosoma brucei | Tb05.5K5.170 | elongation of very long chain fatty acids protein, putative |
Trypanosoma brucei | Tb927.5.4530 | Long chain fatty acyl elongase |
Trypanosoma congolense | TcIL3000_5_5220 | elongation of very long chain fatty acids protein, putative |
Trypanosoma cruzi | TcCLB.509539.30 | fatty acid elongase, putative |
Trypanosoma cruzi | TcCLB.506717.10 | fatty acid elongase, putative |
Toxoplasma gondii | TGME49_242380 | fatty acid elongase |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.5.4530 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.5.4530 this record | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.5.4530 this record | Trypanosoma brucei | significant gain of fitness in procyclic forms | alsford |
Tb927.5.4530 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_0104700 | Plasmodium berghei | Dispensable | plasmo |
TGME49_242380 | Toxoplasma gondii | Essentiality uncertain | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | decreased (PATO:0000468) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | decreased cell proliferation (significant loss of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in procyclic forms . | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | ELOVL fatty acid elongase 2 | Compounds | References |
1 literature reference was collected for this gene.